volume 28 issue 12 pages 3357-3370

Ki-67 gene expression

Publication typeJournal Article
Publication date2021-06-28
scimago Q1
wos Q1
SJR4.866
CiteScore29.0
Impact factor15.4
ISSN13509047, 14765403
Molecular Biology
Cell Biology
Abstract
Ki-67 serves as a prominent cancer marker. We describe how expression of the MKI67 gene coding for Ki-67 is controlled during the cell cycle. MKI67 mRNA and Ki-67 protein are maximally expressed in G2 phase and mitosis. Expression is dependent on two CHR elements and one CDE site in the MKI67 promoter. DREAM transcriptional repressor complexes bind to both CHR sites and downregulate the expression in G0/G1 cells. Upregulation of MKI67 transcription coincides with binding of B-MYB-MuvB and FOXM1-MuvB complexes from S phase into G2/M. Importantly, binding of B-MYB to the two CHR elements correlates with loss of CHR-dependent MKI67 promoter activation in B-MYB-knockdown experiments. In knockout cell models, we find that DREAM/MuvB-dependent transcriptional control cooperates with the RB Retinoblastoma tumor suppressor. Furthermore, the p53 tumor suppressor indirectly downregulates transcription of the MKI67 gene. This repression by p53 requires p21/CDKN1A. These results are consistent with a model in which DREAM, B-MYB-MuvB, and FOXM1-MuvB together with RB cooperate in cell cycle-dependent transcription and in transcriptional repression following p53 activation. In conclusion, we present mechanisms how MKI67 gene expression followed by Ki-67 protein synthesis is controlled during the cell cycle and upon induction of DNA damage, as well as upon p53 activation.
Found 
Found 

Top-30

Journals

2
4
6
8
10
12
International Journal of Molecular Sciences
11 publications, 4.98%
Scientific Reports
8 publications, 3.62%
International Journal of Biological Macromolecules
5 publications, 2.26%
Nature Communications
3 publications, 1.36%
Biomolecules
3 publications, 1.36%
Cell Death and Differentiation
3 publications, 1.36%
Frontiers in Immunology
2 publications, 0.9%
Medicina
2 publications, 0.9%
Heliyon
2 publications, 0.9%
Clinical and Translational Medicine
2 publications, 0.9%
Cancers
2 publications, 0.9%
Cancer Letters
2 publications, 0.9%
iScience
2 publications, 0.9%
bioRxiv
2 publications, 0.9%
Stem Cell Reviews and Reports
2 publications, 0.9%
Current Issues in Molecular Biology
2 publications, 0.9%
Journal of Translational Medicine
2 publications, 0.9%
Biomaterials
2 publications, 0.9%
Proceedings of the National Academy of Sciences of the United States of America
2 publications, 0.9%
Translational Oncology
2 publications, 0.9%
Naunyn-Schmiedeberg's Archives of Pharmacology
2 publications, 0.9%
RSC Advances
2 publications, 0.9%
Medicine (United States)
1 publication, 0.45%
Diagnostics
1 publication, 0.45%
Frontiers in Cardiovascular Medicine
1 publication, 0.45%
Frontiers in Neuroscience
1 publication, 0.45%
Frontiers in Pediatrics
1 publication, 0.45%
Frontiers in Pharmacology
1 publication, 0.45%
Signal Transduction and Targeted Therapy
1 publication, 0.45%
2
4
6
8
10
12

Publishers

10
20
30
40
50
Springer Nature
50 publications, 22.62%
Elsevier
46 publications, 20.81%
MDPI
29 publications, 13.12%
Cold Spring Harbor Laboratory
25 publications, 11.31%
Wiley
19 publications, 8.6%
Frontiers Media S.A.
12 publications, 5.43%
Taylor & Francis
5 publications, 2.26%
Oxford University Press
5 publications, 2.26%
Royal Society of Chemistry (RSC)
4 publications, 1.81%
American Physiological Society
2 publications, 0.9%
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 0.9%
American Chemical Society (ACS)
2 publications, 0.9%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.45%
Society for the Study of Reproduction
1 publication, 0.45%
The Company of Biologists
1 publication, 0.45%
Hindawi Limited
1 publication, 0.45%
Public Library of Science (PLoS)
1 publication, 0.45%
European Molecular Biology Organization
1 publication, 0.45%
AME Publishing Company
1 publication, 0.45%
PeerJ
1 publication, 0.45%
Research Square Platform LLC
1 publication, 0.45%
The Endocrine Society
1 publication, 0.45%
SPIE-Intl Soc Optical Eng
1 publication, 0.45%
Spandidos Publications
1 publication, 0.45%
American Society for Microbiology
1 publication, 0.45%
SciELO
1 publication, 0.45%
Bentham Science Publishers Ltd.
1 publication, 0.45%
Mary Ann Liebert
1 publication, 0.45%
American Society for Clinical Investigation
1 publication, 0.45%
10
20
30
40
50
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
222
Share
Cite this
GOST |
Cite this
GOST Copy
Uxa S. et al. Ki-67 gene expression // Cell Death and Differentiation. 2021. Vol. 28. No. 12. pp. 3357-3370.
GOST all authors (up to 50) Copy
Uxa S., Castillo Binder P., Köhler R., Stangner K., Müller G. A., Engeland K. Ki-67 gene expression // Cell Death and Differentiation. 2021. Vol. 28. No. 12. pp. 3357-3370.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41418-021-00823-x
UR - https://doi.org/10.1038/s41418-021-00823-x
TI - Ki-67 gene expression
T2 - Cell Death and Differentiation
AU - Uxa, Sigrid
AU - Castillo Binder, Paola
AU - Köhler, Robin
AU - Stangner, Konstanze
AU - Müller, Gerd A
AU - Engeland, Kurt
PY - 2021
DA - 2021/06/28
PB - Springer Nature
SP - 3357-3370
IS - 12
VL - 28
PMID - 34183782
SN - 1350-9047
SN - 1476-5403
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Uxa,
author = {Sigrid Uxa and Paola Castillo Binder and Robin Köhler and Konstanze Stangner and Gerd A Müller and Kurt Engeland},
title = {Ki-67 gene expression},
journal = {Cell Death and Differentiation},
year = {2021},
volume = {28},
publisher = {Springer Nature},
month = {jun},
url = {https://doi.org/10.1038/s41418-021-00823-x},
number = {12},
pages = {3357--3370},
doi = {10.1038/s41418-021-00823-x}
}
MLA
Cite this
MLA Copy
Uxa, Sigrid, et al. “Ki-67 gene expression.” Cell Death and Differentiation, vol. 28, no. 12, Jun. 2021, pp. 3357-3370. https://doi.org/10.1038/s41418-021-00823-x.